Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FU2V
|
|||
| Former ID |
DNC010077
|
|||
| Drug Name |
D-237
|
|||
| Synonyms |
CHEMBL457025; BDBM50273939; (R)-6-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H35N3O
|
|||
| Canonical SMILES |
CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)C=CC=C4O
|
|||
| InChI |
1S/C25H35N3O/c1-2-13-27(23-11-12-24-21(20-23)7-6-10-25(24)29)17-14-26-15-18-28(19-16-26)22-8-4-3-5-9-22/h3-10,23,29H,2,11-20H2,1H3/t23-/m1/s1
|
|||
| InChIKey |
ACDYFMOSSUKHJD-HSZRJFAPSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D2 receptor (D2R) | Target Info | Inhibitor | [1] |
| Dopamine D3 receptor (D3R) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Dopaminergic synapse | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Genes and (Common) Pathways Underlying Drug Addiction | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.